Raymond James reiterates CVS Health stock rating ahead of earnings

Raymond James reiterated Outperform and a $120 price target on CVS Health ahead of its November 4 third-quarter report; CVS was cited at $91.41, while the firm left its estimates unchanged. Better-than-expected Medicare Advantage results at peers and stabilizing Medicaid trends are encouraging, but elevated commercial costs and a reported decline in CVS members enrolled in high-rated plans for 2027 remain concerns; TD Cowen estimates the Star-rating decline could have a $720 million financial impact by 2028. Bloomberg options data implies a potential 5.8% stock move after earnings, and a possible retail pharmacy spinoff is reported as under consideration for the first half of 2028.

Analysis

CVS is a conditional earnings setup, not a clean peer-read-through. Better Medicare Advantage (MA) trends at other insurers can lift near-term expectations, but CVS’s reported Star-rating exposure and the estimated $720 million 2028 impact make a strong quarter less valuable if management cannot show a credible path to protect MA economics. The key signal is therefore not just the Q3 beat: it is whether any upside reaches 2026 guidance, and whether 2027 pricing, enrollment and margins offset the rating drag. A beat largely held for Q4, or vague 2027 commentary, risks turning favorable peer data into a sell-the-news event.

The possible retail spin is a distant, unconfirmed catalyst. Separation could sharpen valuation of the pharmacy and benefits businesses, but it does not itself repair MA profitability; execution, stranded costs and allocation of shared operations could erode any sum-of-parts benefit. PBM retention near the cited mid-90s would reduce one source of revenue uncertainty, but verify actual retention and contract economics rather than treating retention alone as proof of durable margins. Near-term volatility is elevated: the reported 5.8% options-implied move argues against paying up for direction before the release. The contrarian risk is that analyst optimism and peer strength are already reflected in expectations, while the less visible 2027 Star-rating and 340B pressures remain unresolved.

Key Decisions for Investors

• Avoid a pre-earnings directional position absent an identified options premium advantage: use the reported 5.8% implied move as an event-risk yardstick, not a forecast. Reassess after the report.
• Consider a staged long CVS only after the release if management converts Q3 strength into firmer 2026 guidance and gives credible 2027 MA pricing, margin and enrollment evidence. Falsify the setup if upside is deferred to Q4 or guidance does not improve.
• Track CVS’s 2027 Star-rating exposure, 340B headwind and PBM retention economics as separate thesis tests. A worsening outlook or retention deterioration would invalidate the recovery case even if reported Q3 earnings beat.
• Treat the reported 2028 retail separation as an alert, not a valuation catalyst to underwrite now. Revisit only if CVS confirms a plan and discloses expected stranded costs, capital allocation and segment economics.